HIF1A and hepatocellular carcinoma: YC-1 is also a HIF-1α inhibitor, so YC-1 may play a assisting role in anti-tumor of sorafenib through the mechanism above, which confirms us that sorafenib-YC-1 combination could be potential for use for HCC patients in near future.